Evidence map›Paper›PMID 40919483›Full record

Trial reportBlood neoplasia2025

Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study.

Mrinal M Patnaik, Haris Ali, Eunice S Wang, Abdulraheem Yacoub, James M Foran, Vikas Gupta, Gary J Schiller, Don Ambrose Stevens, Moshe Talpaz, Sarah Wall and 8 more

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood neoplasia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Mrinal M PatnaikDivision of Hematology, Mayo Clinic, Rochester, MN.
Haris AliDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
Eunice S WangDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
Abdulraheem YacoubDepartment of Internal Medicine, The University of Kansas Cancer Center, Westwood, KS.
James M ForanDivision of Hematology & Medical Oncology, Mayo Clinic Cancer Center, Jacksonville, FL.
Vikas GuptaPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Gary J SchillerDepartment of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA.
Don Ambrose StevensNorton Cancer Institute, Louisville, KY.
Moshe TalpazDepartment of Hematology-Oncology, Rogel Cancer Center, University of Michigan, Ann Arbor, MI.
Sarah WallDivision of Hematology, The Ohio State University, Columbus, OH.
Terra L LashoDivision of Hematology, Mayo Clinic, Rochester, MN.
Abhishek A MangaonkarDivision of Hematology, Mayo Clinic, Rochester, MN.
Talha BadarDivision of Hematology & Medical Oncology, Mayo Clinic Cancer Center, Jacksonville, FL.
Ross LindsayMenarini Group, New York, NY.
Antonio GalleuMenarini Group, Florence, Italy.
Ira GuptaMenarini Group, New York, NY.
Naveen PemmarajuDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic myelomonocytic leukemia (CMML) is an aggressive hematologic neoplasm characterized by an expansion of CD123

Identifiers

PMID40919483
PMCPMC12409811

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.